Insight, China's Pharmaceutical Industry

Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption

The Hainan Boao Lecheng International Medical Tourism Pilot Zone has released the “Implementation Rules for...

BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis

Fineline Cube Sep 11, 2026

The CD19‑targeted genetically modified allogeneic chimeric antigen receptor T‑cell (CAR‑T) injection of Shanghai BRL Medicine,...

Company Drug

Walvax’s Third‑Generation COVID‑19 mRNA Vaccine Wins NMPA Approval – JN.1‑Based Shot Clears Regulatory Bar for Adults in China

Fineline Cube Sep 11, 2026

Walvax Biotechnology Co., Ltd. (SHE: 300142) announced that its COVID‑19 mRNA vaccine has been approved...

Policy / Regulatory

China’s Seventh National VBP Round for Medical Consumables Concludes in Tianjin – 517 Digestive Intervention Products Selected Across 23 Categories

Fineline Cube Sep 11, 2026

The seventh batch of China’s state‑organized centralized volume‑based procurement (VBP) of medical consumables opened bids...

Company Drug

Ocumension’s OT‑301 NDA Accepted by China’s CDE – Dual‑Mechanism Glaucoma Therapy Advances Toward Approval in Open‑Angle Glaucoma and Ocular Hypertension

Fineline Cube Sep 11, 2026

Ocumension Therapeutics (HKG: 1477) announced that the new drug application (NDA) for its key drug...

Company Drug PIC

Allergan Aesthetics’ JUVÉDERM VOLBELLA Wins NMPA Approval for Infraorbital Hollowing – Hyaluronic Acid Filler Expands China Label Beyond Lips

Fineline Cube Sep 11, 2026

Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced that JUVÉDERM VOLBELLA WITH LIDOCAINE has received...

Company Drug PIC

GSK’s Shingrix Wins Japan Approval for Prefilled Syringe Presentation – Recombinant Zoster Vaccine Gains Administration Flexibility

Fineline Cube Sep 11, 2026

GlaxoSmithKline Plc (GSK; NYSE: GSK) announced that Japan’s Ministry of Health, Labour and Welfare (MHLW)...

Company Drug PIC

Hengrui’s Hetrombopag Wins China Approval for CTIT and Pediatric ITP – Oral TPO‑RA Expands Across Thrombocytopenia Indications

Fineline Cube Sep 11, 2026

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that its independently developed Category...

Others

Bayer’s Sevabertinib Granted FDA Accelerated Approval – First‑Line Oral TKI for HER2‑Mutant Non‑Small Cell Lung Cancer

Fineline Cube Sep 11, 2026

Bayer AG (ETR: BAYN) announced that the U.S. Food and Drug Administration (FDA) has granted...

Company Drug PIC

Roche’s Enspryng Granted FDA Priority Review for MOGAD – First IL‑6 Inhibitor Poised to Expand Beyond NMOSD

Fineline Cube Sep 11, 2026

Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY) announced that the U.S. Food and Drug Administration...

Company Deals PIC

Boji Medical and Zhejiang Maiyata Sign Strategic Partnership – Leading China CRO Joins Microbiome Innovator to Advance Live Biotherapeutic Products

Fineline Cube Sep 11, 2026

Boji Medical Technology Co., Ltd. (SHE: 300404), a leading China‑based Clinical Research Organization (CRO), and...

Company Drug

AbbVie’s Atogepant Meets All Endpoints in Phase III LUNA Study – Oral CGRP Antagonist Shows Superior Efficacy in Menstrual Migraine Prevention

Fineline Cube Sep 11, 2026

AbbVie Inc. (NYSE: ABBV) announced positive topline results from its Phase III LUNA study evaluating...

Company Drug PIC

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Fineline Cube Sep 10, 2026

Novo Nordisk A/S (NYSE: NVO) announced that its innovative, long‑acting human growth hormone Sogroya (generic...

Company Deals PIC

Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline

Fineline Cube Sep 10, 2026

Inno Medicine announced that it has completed a Series D financing round of nearly RMB...

Company Drug PIC

Novo Nordisk’s Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis

Fineline Cube Sep 10, 2026

Novo Nordisk A/S (NYSE: NVO) announced that semaglutide injection (brand name: Wegovy) has received approval...

Company Deals

Adagene Achieves New Milestone in SAFEbody ADC Collaboration with Exelixis – USD 2 Million Payment Triggered by Preclinical Progress of ROR1/2‑Targeted XB404

Fineline Cube Sep 10, 2026

Adagene Inc. (NASDAQ: ADAG) announced a new milestone achievement in its ongoing SAFEbody antibody‑drug conjugate...

Company Drug

NMPA Accepts Hengrui’s New Drug Application for Ribupatide Injection – Dual GLP‑1/GIP Receptor Agonist Nears Approval for Type 2 Diabetes in China

Fineline Cube Sep 10, 2026

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that the New Drug Application...

Company Deals

Lee’s Pharmaceutical Secures Exclusive Greater China License for OC‑3 – Next‑Generation PARP1‑Selective Inhibitor from US Biotech 1cBio Targeting BRCA‑Mutant Cancers

Fineline Cube Sep 10, 2026

Lee’s Pharmaceutical Holdings Limited (HKG: 0950) announced that it has entered into an exclusive licensing...

Company Deals PIC

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Fineline Cube Sep 10, 2026

METiS Therapeutics (HKG: 7666) holding company METiS Life Sciences and JOINN Biologics officially signed a...

Company Drug PIC

Merck Launches Clesrovimab in China – World’s First Single Fixed‑Dose, Long‑Acting RSV Monoclonal Antibody Now Commercially Available for Infant Protection

Fineline Cube Sep 10, 2026

Merck & Co., Inc. (MSD; NYSE: MRK) announced that clesrovimab injection, the world’s first single...

You Missed